The "brittle response" to Parkinson's disease medications: characterization and response to deep brain stimulation.
<h4>Objective</h4>Formulate a definition and describe the clinical characteristics of PD patients with a "brittle response" (BR) to medications versus a "non-brittle response" (NBR), and characterize the use of DBS for this population.<h4>Methods</h4>An UF...
Guardado en:
Autores principales: | Daniel Martinez-Ramirez, Juan Giugni, Vinata Vedam-Mai, Aparna Wagle Shukla, Irene A Malaty, Nikolaus R McFarland, Ramon L Rodriguez, Kelly D Foote, Michael S Okun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/34ebfaef1fce4beb9f7668df8e050de1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.
por: Nawaz Hack, et al.
Publicado: (2014) -
Wearable sensor-driven responsive deep brain stimulation for essential tremor
por: Stephanie Cernera, et al.
Publicado: (2021) -
Brittle cornea syndrome: current perspectives [Response to Letter]
por: Walkden A, et al.
Publicado: (2019) -
Management of deep brain stimulator battery failure: battery estimators, charge density, and importance of clinical symptoms.
por: Kaihan Fakhar, et al.
Publicado: (2013) -
Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome.
por: Sarah J Moum, et al.
Publicado: (2012)